The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: Clinical and demographic characteristics

Neuroscience Letters

Volumn 537, Issue , 2013, Pages 1-5

  Gatto, Emilia Mabel ^a,b   Parisi, Virginia ^b   Converso, Daniela Paola ^c   Poderoso, Juan José ^c   Carreras, María Cecilia ^c   Martí Massó, José Felix ^d   Paisán Ruiz, Coro ^e  

^a Instituto Neurociencias de Buenos Aires ^*  (Argentina)

^b Sanatorio de la Trinidad   (Argentina)

^c HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^d HOSPITAL DONOSTIA   (Spain)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Genetics; Immunology; Parkinson's disease; Parkinsonism

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

AGED; ARGENTINA; ARTICLE; BLOOD SAMPLING; CELIAC DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DNA EXTRACTION; DYSKINESIA; EDUCATION; EXON; FAMILY HISTORY; FEMALE; GENE MUTATION; HALLUCINATION; HASHIMOTO DISEASE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURED INTERVIEW; TREMOR; VISUAL HALLUCINATION;

ADULT; AGED; AGED, 80 AND OVER; ARGENTINA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HETEROZYGOTE; HUMANS; JEWS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PEDIGREE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84874349443     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.01.011     Document Type: Article

References (24)

1. Alcalay R.N., Mejia-Santana H., Tang M.X., Rosado L., Verbitsky M., Kisselev S., Ross B., Louis E.D., Comella C., Colcher A., Jennings D., Nance M., Bressman S., Scott W.K., Tanner C., Mickel S., Andrews H., Waters C., Fahn S., Cote D., Frucht S., Ford B., Rezak M., Novak K., Friedman J.H., Pfeiffer R., Marsh L., Hiner B., Siderowf A., Caccappolo E., Ottman R., Clark L.N., Marder K. Motor phenotype of LRRK2 G2019S carriers in Early Onset Parkinson Disease. Archives of Neurology 2009, 66:1517-1522.
2. Avena S.A., Goicochea A.S., Rey J. Mezcla génica en una muestra poblacional de la ciudad de Buenos Aires. Medicina 2006, 66:113-118.
3. Begué C., Beratarrechea A.G., Varela E., Piccioni H.L., Rodota L., Castro M.E., Koll M.F., Bustos D., Dawidowski A., Langlois E., Marchetti M., De Paula J.A. Celiac disease: diagnosis prevalence in a community hospital. Acta Gastroenterologica Latinoamericana 2010, 40:317-322.
4. Benamer H.T., de Silva R. LRRK2 G2019S in the North African population: a Review. European Neurology 2010, 63:321-325.
5. Bonuccelli U., D'Avino C., Caraccio N., Del Guerra P., Casolaro A., Pavese N., Del Dotto P., Monzani F. Thyroid function and autoimmunity in Parkinson's disease: a study of 101 patients. Parkinsonism & Related Disorder 1999, 5:49-53.
6. Criscuolo C., De Rosa A., Guacci A., Simons E.J., Breedveld G.J., Peluso S., Volpe G., Filla A., Oostra B.A., Bonifati V., De Michele G. The LRRK2 R1441 C mutation is more frequent than G2019S in Parkinson's disease patients from southern Italy. Movement Disorders 2011, 26:1733-1736.
7. Corach D., Lao O., Bobillo C., Van Der Gaag K., Zuniga S., Vermeulen M., Van Duijn K., Goedbloed M., Vallone P.M., Parson W., De Knijff P., Kayser M. Inferring continental ancestry of argentineans from autosomal, Y-Chromosomal and mitochondrial DNA. Annals of Human Genetics 2010, 74:65-76.
8. Freeman H.J., Chopra A., Clandinin M.T., Thomson A.B.R. Recent advances in celiac disease. World Journal of Gastroenterology 2011, 17:2259-2272.
9. Goldwurm S., Tunesi S., Tesei S., Zini M., Sironi F., Primignani P., Magnani C., Pezzoli G. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease. Movement Disorders 2011, 26:2144-2145.
10. Hakimi M., Selvanantham T., Swinton E. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and up regulated following recognition of microbial structures. Journal of Neural Transmission 2011, 118:795-808.
11. Hamza T.H., Zabetian C.P., Tenesa A. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nature Genetics 2010, 42:781-785.
12. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., Brice A., Aasly J., Zabetian C.P., Goldwurm S., Ferreira J.J., Tolosa E., Kay D.M., Klein C., Williams D.R., Marras C., Lang A.E., Wszolek Z.K., Berciano J., Schapira A.H., Lynch T., Bhatia K.P., Gasser T., Lees A.J., Wood N.W. International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology 2008, 7:583-590.
13. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M., Simón-Sánchez J., Schulte C., Lesage S., Sveinbjörnsdóttir S., Stefánsson K., Martinez M., Hardy J., Heutink P., Brice A., Gasser T., Singleton A.B., Wood N.W. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet 2011, 377:641-649. International Parkinson Disease Genomics Consortium.
14. Marras C., Schuele B., Munhoz R.P., Rogaeva E., Langston J.W., Kasten M., Meaney C., Klein C., Wadia P.M., Lim S.Y., Chuang R.S., Zadikof C., Steeves T., Prakash K.M., de Bie R.M., Adeli G., Thomsen T., Johansen K.K., Teive H.A., Asante A., Reginold W., Lang A.E. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011, 77:325-333.
15. Mata I.F., Cosentino C., Marca V., Torres L., Mazzetti P., Ortega O., Raggio V., Aljanati R., Buzo R., Yearout D., Dieguez E., Zabetian C.P. LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. Parkinsonism and Related Disorders 2009, 15:370-373.
16. Mata I.F., Wilhoite G.J., Yearout D., Bacon J.A., Cornejo-Olivas M., Mazzetti P., Marca V., Ortega O., Acosta O., Cosentino C., Torres L., Medina A.C., Perez-Pastene C., Díaz-Grez F., Vilariño-Güell C., Venegas P., Miranda M., Trujillo-Godoy O., Layson L., Avellom R., Dieguez E., Raggio V., Micheli F., Perandones C., Alvarez V., Segura-Aguilar J., Farrer M.J., Zabetian C.P., Rossc O.A. Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America. Parkinsonism and Related Disorders 2011, 17:629e-631e.
17. Mattos Gonc M., Pimentel A., Vasconcelos Mouraa K.C., Bueno Abdalla C., Santos Pereira J., Zuma de Rosso A.L., Hack Nicaretta D., Campos Junior M., Morais de Almeida R., Mendonc J., dos Santos A., Constantino Bastos I.C., Xavier Mendese M.F., Maultasch H., de Rezende Costa F.H., dos Santos Werneck A.L., Barros Santos-Rebouc C. A study of LRRK2 mutations and Parkinson's disease in Brazil. Neuroscience Letters 2008, 433:17-21.
18. Paisan-Ruiz C. LRRK2 gene variation and its contribution to Parkinson's disease. Human Mutation 2009, 30:1153-1160.
19. Paisán-Ruiz C., Nath P., Washecka N., Gibbs J.R., Singleton A.B. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Human Mutation 2008, 29:485-490.
20. Perez-Pastene C., Cobb S.A., Di{dotless}az-Grez F., Hulihan M.M., Miranda M., Venegas P., Trujillo Godoy O., Kachergus J.M., Ross O.A., Layson L., Farrer M.J., Segura-Aguilar J. Lrrk2 mutations in South America: a study of Chilean Parkinson's disease. Neuroscience Letters 2007, 42:193-197.
21. Ruiz-Martínez J., Gorostidi A., Ibañez B., Alzualde A., Otaegui D., Moreno F., López de Munain A., Bergareche A., Gómez-Esteban J.C., Martí Massó J.F. Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain). Movement Disorders 2010, 25:2340-2345.
22. San Luciano M., Lipton R.B., Wang C., Katz M., Zimmerman M.E., Sanders A.E., Ozelius L.J., Bressman S.B., Saunders-Pullman R. Clinical Expression of LRRK2 G2019S Mutations in the Elderly. Movement Disorders 2010, 25:2571-2576.
23. Teixeira Camargos S., Oliveira Dornas L., Momeni P., Lees A., Hardy J., Singleton A., Cardoso F., Familial Parkinsonism and early onset Parkinson's disease in a Brazilian Movement Disorders clinic: Phenotypic characterization and frequency of SNCA, PRKN, PINK1 and LRRK2 mutations. Movement Disorders 2009, 24:662-666.
24. Tong Y., Yamaguchi H., Giaime E. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:9879-9884.